In chronic lymphocytic leukemia (CLL), the microenvironment influences gene expression patterns; however, knowledge is limited regarding the extent to which methylation changes with time and exposure to specific microenvironments. Using high-resolution 450K arrays, we provide the most comprehensive DNA methylation study of CLL to date, analyzing paired diagnostic/follow-up samples from IGHV-mutated/untreated and IGHV-unmutated/treated patients (n ¼ 36) and patient-matched peripheral blood and lymph node samples (n ¼ 20). On an unprecedented scale, we revealed 2239 differentially methylated CpG sites between IGHVmutated and unmutated patients, with the majority of sites positioned outside annotated CpG islands. Intriguingly, CLL prognostic genes (for example, CLLU1, LPL, ZAP70 and NOTCH1), epigenetic regulator (for example, HDAC9, HDAC4 and DNMT3B), B-cell signaling (for example, IBTK) and numerous TGF-b and NF-kB/TNF pathway genes were alternatively methylated between subgroups. Contrary, DNA methylation over time was deemed rather stable with few recurrent changes noted within subgroups. Although a larger number of non-recurrent changes were identified among IGHV-unmutated relative to mutated cases over time, these equated to a low global change. Similarly, few changes were identified between compartment cases. Altogether, we reveal CLL subgroups to display unique methylation profiles and unveil methylation as relatively stable over time and similar within different CLL compartments, implying aberrant methylation as an early leukemogenic event.
INTRODUCTION
Aberrant DNA hypermethylation driven gene silencing of tumor suppressor genes is today recognized as a key event in cancer pathogenesis. 1, 2 So far, investigations focusing on CpG sites at single gene promoters and CpG islands in chronic lymphocytic leukemia (CLL) have revealed a number of aberrantly methylated genes of biological and clinical importance, for example, DAPK1 ZAP70, TWIST2, HOXA4, SFRP4 and ID4. [3] [4] [5] [6] [7] [8] More recently, the advent of microarray allowing global methylation screening has revealed a number of functionally diverse aberrantly methylated genes and pathways in CLL. [9] [10] [11] [12] Using 27K DNA methylation microarrays, we previously recognized a differential methylation pattern distinguishing favorable prognostic IGHV-mutated (IGHV-M) from poor-prognostic IGHV-unmutated (IGHV-UM) CLL patients. 11 Interestingly, we identified several tumor suppressor genes (for example, ABI3 and WISP3) 13, 14 differentially methylated between these subgroups and noted a number of proliferationrelated genes to remain unmethylated and potentially expressed within the unfavourable as IGHV-UM subgroup. Furthermore, DNA methylation interrogation by arrays has also identified a number of differentially methylated genes to segregate according to CD38 expression status in CLL. 10 Although aberrant DNA methylation events are often suggested as early pathogenic events, little is known regarding DNA methylation changes over time, particularly for CLL. In addition, knowledge concerning the extent to which the microenvironment shapes the tumor epigenetic profile is limited. It is well known that the microenvironment is key to CLL pathobiology, 15 where proliferation centers in lymphoid tissue are hubs of cell proliferation allowing up to 1% of the clone to proliferate daily. 16 Recently, gene expression profiling of lymph node (LN)-derived CLL cells also identified high expression of genes involved in B-cell receptor (BCR) signaling and proliferation relative to cells from the resting peripheral blood (PB) compartment. 17 Given that we previously identified IGHV-M and IGHV-UM CLL to have differential methylation profiles and in light of the contribution of time and microenvironment to gene expression, 11, 17 we sought to determine DNA methylation changes occurring over time and changes attributed to alternative microenvironments. To gain insights into these issues, we here applied 450K DNA methylation arrays (including 4450 000 CpG sites) on diagnostic and follow-up samples from treated IGHV-UM and untreated IGHV-M CLL patients as well as from patientmatched PB and LN samples. On a larger scale than previously published, 11 we identified a large number of differentially methylated CpG sites between prognostic subgroups, and, for the first time revealed that the methylation patterns were stable over time and between compartments.
MATERIALS AND METHODS

Patients and controls
To assess the global DNA methylation profiles in different prognostic subgroups of CLL, PB samples collected at diagnosis from nine IGHV-M and nine IGHV-UM patients were included for analysis. Approximately 5-8 years later (median 6.8 years), a follow-up PB sample from the same IGHV-M and IGHV-UM patients was obtained to study DNA methylation over time. Between first and second sampling points, all IGHV-M patients had remained untreated, while all IGHV-UM patients had subsequently been treated. The median age of this cohort at diagnosis was 63 years (range, 47-73 years) and consisted of 7 males and 11 females. All samples were obtained from the Swedish division of the Scandinavian population-based case-control study called SCALE (Scandinavian Lymphoma Etiology). 18 To determine the DNA methylation profiles of CLL cells derived from different compartments, a separate set of 20 CLL samples encompassing 10 patientmatched PB and LN samples were obtained from Biobanks at Uppsala and Linkö ping University hospitals. The median age for these patients was 58 years and the ratio of males to females was 4:1. Eight of the ten CLL patients were untreated at sampling. Three patient-matched PB and LN paired cases were simultaneously retrieved, six were collected within 1 month (range, 2-4 weeks) and 1 pair was sampled a year apart.
All CLL samples were diagnosed according to recently revised criteria, showing a typical CLL immunophenotype. 19 Normal B cells isolated form three individuals aged 51, 65 and 66 years were included as controls and one whole-genome amplified DNA sample was included as a negative control. Informed consent was collected according to the Helsinki Declaration and ethical approval was granted by ethical review committees at Uppsala and Linkö ping Universities. Molecular and clinical data for all patients are summarized in Supplementary Table 1A and B. B-cell enrichment and CLL cell sorting All 36 PB CLL samples collected to study DNA methylation over time originally contained 470% tumor cells. To enrich for tumor cells, all samples were subjected to negative depletion according to standard protocols devised by the Stem cell technologies B cell enrichment kit (Stem Cell, Grenoble, France). Tumor cell purity was then assessed by FACS analysis of CD5 and CD19 cell surface markers. A purity of X94% (mean 96%) was obtained for all samples. Normal B-cell controls were enriched in the same manner. In contrast, the 20 patient-matched PB and LN samples collected to study DNA methylation within different CLL compartments were CD5/CD19 sorted by flow cytometry.
450K methylation analysis
High quality DNA was bisulfite converted using the EZ DNA Methylation gold Kit (Zymo Research, Irvine, CA, USA) according to manufacturer's instructions. Converted DNA was then hybridized to the HumanMethylation450 Analysis BeadChip and processed following the Illumina Infinium 450K Methylation array assay procedure (Illumina, San Diego, CA, USA). Hybridization fluorescent signals were read by the Illumina BeadStation GX scanner. A beta value, a quantitative measure of DNA methylation was then assigned via the bead studio software (Illumina). This value was calculated from the ratio of fluorescent signals from the methylated alleles to the sum of the signals from the methylated and unmethylated alleles. Upon transformation of the data, beta values ranged from 0 (completely unmethylated) to 1.3 (completely methylated) over the different CpG sites studied.
Bioinformatic analysis was conducted using the Illumina methylation analyzer (IMA) package. Raw data were quantile normalized and arcsin transformed. To determine differential methylation patterns between IGHV-M and IGHV-UM CLL patients at diagnosis, an empirical Bayes moderated t-test was employed using the limma package. P-values were adjusted using the Benjamini and Hochberg method 20 and a P-value of p0.05 was applied as a cutoff. A further filter of X0.40 in average beta difference between the diagnostic IGHV-M/UM sample sets was used to ensure that only recurrent CpG sites with a large methylation difference were obtained. Results were visualized by means of a heat-map using the genesis program (http://genome.tugraz.at) and three normal B-cell controls were included for comparison purposes. Ingenuity pathway analysis (IPA) software was utilized for gene ontology and pathway analysis to delineate the differentially methylated genes between the CLL subgroups (http://www.ingenuity.com).
To identify methylation differences between paired diagnostic and follow-up samples and matched samples from different compartments, data were pre-processed in the same way as above; however, a paired t-test was adopted to define recurrent changes. Recurrent changes over time were identified using a filter of 40.2 in average beta difference between the diagnostic and follow-up samples. To identify non-recurrent differences that ordinarily would be masked by transformation and averaging of the DNA methylation data, an intra-individual sample paired analyses on non-transformed data was performed on the over time and compartment samples using a cutoff of X0.40 in beta difference.
Pyrosequencing
To validate the array, DNA methylation quantitation of the exact CpG site targeted by the array was measured via pyrosequencing analysis. CpG sites covering three genes (HDAC4, HDAC9 and CLLU1) were chosen for validation using samples originally run on the array (primers are available upon request). To determine the DNA methylation status of the differentially methylated LPL gene not only at the single CpG site targeted by the array, pyrosequencing of multiple sites across the CpG island (five sites) and gene promoter (two sites) were also chosen for analysis. This latter analysis was conducted on a set of independent non-sorted patient samples that were previously not run on the array. Test samples were bisulfite converted using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA), PCR amplified and denatured according to standard protocols (Qiagen, Venlo, Netherlands). Quantitative methylation analysis was then performed on the PyroMark Q24 instrument (Qiagen). Epitect fully converted and unconverted DNA controls were included for analysis (Qiagen).
RESULTS
A comparison of global DNA methylation between IGHV mutated and unmutated CLL Genome-wide DNA methylation profiles were compared between newly diagnosed IGHV-M (n ¼ 9) and IGHV-UM (n ¼ 9) CLL patients. Using stringent selection criteria (as described in Materials and methods), a total of 2239 sites were deemed as differentially methylated between these subgroups ( Figure 1) . A spatial view of these sites mapped across the genome (chromosomes revealed no bias in the distribution across all chromosomes (Supplementary Figure 1) . A regional analysis of these sites in relation to CpG islands revealed the majority of sites to be positioned outside of known annotated CpG islands. More specifically, B7% were located in CpG islands (149/2239 sites), 22% in shores (492/2239 sites), 13% in shelves (297/2239 sites) and 58% (1301/2239 sites) lay in non-annotated regions in relation to the CpG island. Hence, of the available annotated regions, B16% were located in islands, 52% in shores and 32% in shelves. Investigations into the position of these differentially methylated sites across the gene structure noted a large proportion of them to be situated within the gene body (Supplementary Figure 2) .
IPA ontology analysis of the 1826 differentially methylated genes identified by the array demonstrated a number of enriched physiological and molecular functionalities as described in Table 1 . Most of the genes contained within these functions have not been implicated in CLL previously. However, many of these were identified as members of recognized signaling pathways, whereas others were known to have roles in other cancers. A summary of the methylation status of a selection of these genes and the position of their targeted CpG sites is given in Table 2 and  Supplementary Table 2 . For comparison purposes, the methylation status of these select genes within the normal B-cell controls is additionally provided in Table 2. A focused search for genes clinically associated with CLL revealed a number of well-known CLL prognostication genes. Interestingly, we identified the differential methylation profiles of DNA methylation over time and within different compartments of CLL N Cahill et al key CLL prognosticator genes, such as ZAP70, LPL and CLLU1.
4,21-23
More specifically, higher DNA methylation of the CLLU1 gene was present in IGHV-M CLL and normal B-cell controls relative to the IGHV-UM cases. Similarly, higher DNA methylation of the LPL gene, within the transcription start site TSS1500/shore and gene body/ shore regions, was evidenced in IGHV-M and normal B cells compared with IGHV-UM CLL. In line with previous data, 4 IGHV-M cases were also found to have higher DNA methylation of the ZAP70 gene compared with IGHV-UM CLL (Table 2; Supplementary  Table 2 ). Interestingly, we found NOTCH1, a newly identified mutated gene in CLL 24, 25 to have higher methylation within the gene body/shore region of IGHV-M patients and healthy individuals relative to IGHV-UM cases.
An investigation of genes of possible biological importance in CLL unveiled a number of proliferation and apoptosis-associated genes (for example, LEF-1 and TCF3) BCR signaling genes (for example, IBTK) and epigenetic regulator genes (for example, HDAC4, HDAC9 and DNMT3B) as differentially methylated (Table 2;  Supplementary Table 2) . [26] [27] [28] [29] [30] [31] Interestingly, this array study could also reiterate the preferential methylation of tumor suppressor genes ABI3
(ref. 13) in IGHV-UM and WISP3 (ref. 14) in IGHV-M subgroups as seen in our earlier 27K-array study 11 ( Table 2; Supplementary  Table 2 ). Moreover, we reconfirmed CD80 and CD86, the B cell co-stimulating molecules, 32 to be hypermethylated in IGHV-UM relative to IGHV-M cases. 11 One of the enriched canonical pathways highlighted through IPA analysis was the 'molecular mechanisms of cancer pathway'. Superimposing our data set onto this pathway, differentially methylated genes were sorted into pathways known to be involved in cancer. Following a literature review of these pathways, only genes from the more established genes/pathways previously implicated in CLL were further investigated. Nine key Neg -0. Figure 1. Heat map demonstrating supervised hierarchical clustering of methylated and unmethylated genes between IGHV-mutated and unmutated CLL subgroups. Three normal healthy B cell control samples (Con 1-3) and one negative whole-genome amplified control (Neg) were included for comparison purposes. A gradient color scale ranging between green (completely unmethylated) to red (completely methylated) is shown.
genes belonging to the TGF-b pathway and thirteen components of the NF-kB/TNF pathway were identified. The methylation status of the CpG site(s) and the gene region interrogated by the array for the various genes contained within these pathways categorized according to the IGHV mutational status are described in Table 3 and Supplementary Table 3 .
A comparison of genome-wide DNA methylation over time On searching for recurrent methylation changes using strict criteria (P ¼ 0.05 and an average beta difference of 40.20) , no recurrent differentially methylated sites were noted over time within the IGHV-M subgroup. Under the same criteria, only six recurrent sites covering five genes (LNX1, OTP, PDGFRA, HOXA11A and LOC400927) were found to be differentially methylated over time in the IGHV-UM cases.
To identify smaller recurrent changes over time, we solely employed a cutoff of P ¼ 0.05 and omitted the use of a further filter in average beta difference. Only four sites with small changes (range, 0.04-0.06 mean beta difference) in methylation were observed in the IGHV-M cases. The magnitude of these small changes was larger within the unmutated subgroup, here 43 sites presented with small changes. Of the aforementioned sites, 70% changed by an average beta difference in the range of 0.05-0.10 and the remainder in the range of X0.10 to p0.20. Within the IGHV-M and IGHV-UM subgroups studied, approximately half of these small DNA methylation changes were shown to increase and the remaining half to decrease over time.
To estimate the likelihood that these small methylation changes represent technical array changes, R 2 values for the paired over time IGHV-M and IGHV-UM samples were compared with the R 2 value obtained by Illumina for their technical replicates. R 2 values for the IGHV-M paired samples were shown to be in the same range (499%) as the technical replicates quoted by Illumina (o98%); however, R 2 values for the IGHV-UM pairs (94-98%) were not entirely within the range quoted by Illumina for their technical replicates. Hence, these small changes could not be deemed as being truly biological or technical in nature.
To identify changes masked by transformation and averaging, intra-individual patient analyses were applied. Analysis revealed IGHV-UM patients to have higher number of differentially methylated sites (X0.40) compared with IGHV-M patients Po0.001. More specifically, the total number of sites shown to differ over time within the IGHV-UM patients ranged from 125 to 3243, equating to a global change of 0.03-0.67% (median, 0.27%). In contrast, the total number of sites differing over time within the IGHV-M cases ranged from 9 to 38, equating to 0-0.01% genomewide change. Defined by a beta difference of X0.40, the majority of differentially methylated sites in IGHV-UM patients (89.1-98.2%) had an absolute beta difference in the range of 0.40-0.59. Approximately half of the sites showed a decrease and the remaining half an increase in methylation over time.
DNA methylation in patient-matched CLL cells from alternative compartments On analyzing the patient-matched CLL material derived from the LN and PB using the same stringent criteria as described above (P ¼ 0.05 and an average beta difference of 40.20) , no recurrent differences in DNA methylation could be detected. Using solely a cutoff of P ¼ 0.05 and no filter in an average beta difference, only a single small recurrent change (0.08 in average beta difference) covering the MICALL2 gene was noted. Of note, the R 2 values reported for patient-matched compartment samples (498%) were analogous to the technical replicate values reported by Illumina.
Intra-individual analysis using a cutoff of X0.40 revealed between 4 and 78 non-recurrent CpG sites to be differentially methylated between patient-matched PB and LN samples. In global terms, this translated into a 0-0.02% global change. Given the lack of change determined under such strict criteria, a less strict cutoff of X0.30 was applied. Under this criterion, 16-277 non-recurrent CpG sites were found to be differentially methylated, translating into a 0-0.06% global change The majority of these non-recurrent differentially methylated sites (50-89.8%) were found to have an absolute beta difference in the range of 0.30-0.39.
Array validation
Two epigenetic regulator genes, HDAC4, HDAC9 and the CLL prognostic gene CLLU1 found to be differentially methylated were validated by bisulfite pyrosequencing (Figures 2a and c) . 23, 29, 30 Additionally, pyrosequencing analysis established IGHV-M cases to have higher DNA methylation across the multiple CpG sites spanning the CpG island (five sites) and promoter (two sites) of the CLL prognostic gene LPL compared with IGHV-UM cases. 22 In general, IGHV-M cases were more heterogeneous in terms of DNA methylation across the latter sites between patients compared with IGHV-UM patients (Figure 2a) . To demonstrate the possible functional link between DNA methylation and gene expression, previously published RQ-PCR gene expression results 33 from two of our highly methylated CLL prognostic genes CLLU1 and LPL were correlated with the methylation levels, revealing a lower gene expression in hypermethylated IGHV-M cases relative to their less methylated IGHV-UM counterparts (Figure 2b ). DNA methylation over time and within different compartments of CLL N Cahill et al DISCUSSION Genome-wide DNA methylation approaches are helping to dismantle the complex landscape of DNA epi-mutations and their role in CLL. [9] [10] [11] [12] 34, 35 Using 27K arrays, we previously discovered prognostically divergent IGHV-M and IGHV-UM CLL to have differential DNA methylation profiles. 11 Here, on a significantly larger scale, 450K methylation array analysis revealed IGHV-M and IGHV-UM subgroups to display a large number of differentially methylated sites (2239 CpG cites), and, for the first time, demonstrated the majority of these sites to be located outside annotated CpG islands. Traditionally, it is accepted that the majority of functionally relevant DNA methylation occurs within the CpG islands of vital gene promoters. 36 However, the significance of altered DNA methylation outside these regions is becoming more apparent. 35, 37 For example, our 27K analysis identified DNA methylation of a CpG site positioned B1 kb away from the promoter of the ADORA3 gene to negatively correlate to ADORA3 gene expression in CLL. 11 Correspondingly in colon cancer, Irizarry et al. 37 have noted that the majority of altered DNA methylation present in CpG island shores (up to 2 kb distant from the CpG island) to functionally relate to gene expression. Similarly, in this study, of the CpG sites within a known annotated region in relation to the CpG island we report a large proportion of differentially methylated sites to be located outside the CpG islands; 52% were found in CpG island shores, 32% in shelves and a mere 16% in CpG islands. Altogether, these findings suggest DNA methylation over time and within different compartments of CLL N Cahill et al aberrant DNA methylation to play a role in establishing the variable disease course seen in prognostic subgroups of CLL and highlight the potential importance of non-CpG island epimutations in leukemogenesis. When searching for differentially methylated genes of clinical significance in CLL, higher DNA methylation at CpG sites within the CLLU1 and LPL genes was revealed in IGHV-M versus IGHV-UM cases. In CLL, high LPL and CLLU1 expression is associated with the presence of IGHV-UM genes and poor clinical outcome. 22, 23 Accordingly, we could also correlate the DNA methylation status to gene expression data for these two genes. Hence, these novel data clearly indicate a possible mode of direct regulation by DNA methylation leading to the differential expression of these CLL prognostic genes. In accordance with a recent study, 4 we also showed ZAP70 to be preferentially methylated in IGHV-M relative to IGHV-UM CLL. Considering that gene expression correlates to DNA methylation status, analysis of DNA methylation marks by pyrosequencing may hence potentially offer an alternative mode of analysis for the aforementioned prognostic genes in a clinical setting. 38 Interestingly, we also identified NOTCH1, a novel mutated gene in CLL, 24, 25 to be more methylated within the gene body/ shore region of IGHV-M patients compared with IGHV-UM patients, nevertheless the functional and clinical relevance of this finding remains to be further investigated.
Investigation of genes of possible biological significance in CLL identified the IBTK gene, an inhibitor of BTK, 28 a key member in BCR signaling and current target of interest for the use of small molecule inhibitors as a novel approach to CLL treatment. 39 DNA methylation over time and within different compartments of CLL N Cahill et al Interestingly, we found the inhibitor IBTK gene to be highly methylated at the TSS1500/shore region of the gene in IGHV-UM patients. It is therefore possible that methylation of the IBTK gene may contribute to the higher rate of BCR signaling, proliferation and disease progression experienced by poor-prognostic IGHV-UM patients. Altogether, this novel finding pinpoints a potential mechanism for the regulation of BTK function in CLL cells which deserves further investigation. Altered histone deacetylase (HDAC) expression levels have been described in hematological malignancies. 30, 40 For instance, high HDAC4 expression was noted in T cell acute lymphoblastic leukemia, 40 and elevated HDAC9 was evident in CLL 30 and childhood acute lymphoblastic leukemia 40 and was indicative of a poor prognosis. Here, we found several CpG sites within the HDAC4 and HDAC9 genes to be preferentially methylated in IGHV-UM, which was also verified by pyrosequencing. Given the potential use of HDAC inhibitors in CLL treatment, 29 the finding of differential methylation of HDAC genes in specific subgroups of CLL may potentially lead to an altered response to such drugs, even though this must be studied further.
Furthermore, when searching for pathways and single gene components belonging to key signaling complexes important for CLL, survival/proliferation pathway mediators LEF1 and TCF3, known effectors of the Wnt pathway in regulating B-cell proliferation, 26, 27 were found to be more methylated among IGHV-M patients. Additionally, a number of genes occupying or controlled by key canonical pathways (NF-kB/TNF and TGF-b) were denoted as differentially methylated in CLL (Table 3) . For instance, the NF-kB/TNF pathway mediators such as TNF, an autocrine growth factor in CLL, 5, 41, 42 was shown to be primarily methylated within IGHV-UM CLL, while TNFRSF8, a receptor molecule, was deemed more methylated among IGHV-M cases. In addition, we noted the downstream transcription factor NF-kB1 to be preferentially methylated in IGHV-UM CLL. Admittedly, relating the methylation status of these genes to pathway function is a challenge since many genes show variable and sometimes alternative methylation at sites within different gene regions. Although complex, our data support the notion that aberrant DNA methylation contributes to the deregulation of known pathways in CLL pathogenesis. Currently, the extent to which DNA methylation levels change with respect to time and treatment is largely undetermined in cancer. Our data presented here recognized DNA methylation as relatively stable over time among IGHV-M/untreated and IGHV-UM/treated CLL patients. Considering the long time period between the first and second sampling points (B5-8 years) and given the ability of the array to interrogate 4485 000 CpG sites, few to no recurrent sites differed in DNA methylation level over time, even if treatment was given between diagnosis and follow-up. The majority of the recurrent differences encountered during the disease course were small methylation changes (between 5 and 19% in average beta difference). However, these could not be verified as being truly biological, since the biological replicate values were in the same range as the technical replicate values quoted by Illumina. On the other hand, the lack of methylation changes may partially be explained by the heterogeneity among the samples, which could mask such changes by the averaging and transformation of the array data. Instead, intraindividual analysis may reveal such DNA methylation changes. Using this alternative approach, a significant difference in the number of non-recurrent differentially methylated sites (X0.40) between IGHV-UM CLL and IGHV-M patients was identified, although these differences again led to subtle changes on a global level (median 0.27% in IGHV-UM CLL). Akin to the scenario where IGHV-UM patients are more likely to acquire genomic alterations over time [43] [44] [45] these above findings indicate that the aggressive nature of IGHV-UM CLL condones the acquisition of a higher number of 'passenger' epi-mutations during clonal evolution.
CLL cells are known to circulate between the PB and LN. While PB CLL cells maintain in a resting state, on journeying to the LN, CLL cells interact with a pro-survival microenvironment in proliferation centers provoking B1% of CLL to proliferate per day. 16 Recently, differential expression profiles have been reported for patient-matched samples originating from the LN and PB in CLL. 17 More specifically, genes involved in proliferation and active BCR signaling were shown to be highly expressed in the LN compared with the PB. Given the reverse correlation to gene expression, we hypothesized that DNA methylation may partake in the mechanism of differential gene expression seen within the different compartments of CLL. In contrast to our assumption, however, the global DNA methylation was rather similar in patient-matched CLL cells derived from resting and proliferative compartments, since few/no recurrent changes were noted and a limited number of non-recurrent changes were detected. Overall, it appears that unlike gene expression, DNA methylation of CLL cells from different compartments is less influenced by microenvironmental factors.
In conclusion, this study highlights the extensive differential methylation profiles in IGHV-M and IGHV-UM CLL, here analyzed on a larger scale than before. Important novel findings include the preferential DNA methylation of CpG sites within known CLL prognostic genes, such as CLLU1 (ref. 23) and LPL, 22 which for the first time points to a direct role of DNA methylation in regulating these genes. Additionally, key components of TGF-b and NF-kB/ TNF pathways and a number of proliferation-related, BCR signaling and epigenetic regulating genes were identified as differentially methylated in IGHV-M and IGHV-UM CLL. Finally, global DNA methylation was deemed to be relatively stable over time and remarkably similar within different CLL compartments, implicating aberrant DNA methylation as early events during CLL development.
